http://orcid.org/0000-0002-6309-8194
References
- Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18:1637–1647.
- Yamazaki Y, Tamada T, Kasai N, Urakawa I, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23:1509–1518.
- Yoshiko Y, Wang H, Minamizaki T, et al. Mineralized tissue cells are a principal source of FGF23. Bone. 2007;40:1565–1573.
- Fukumoto S. Physiological regulation and disorders of systemic phosphate metabolism –pivotal role of fibroblast growth factor 23. Intern Med. 2008;47:337–343.
- Erben RG. Update on FGF23 and Klotho signaling. Mol Cell Endocrinol. 2016;432:56–65.
- Koller L, Kleber ME, Brandenburg VM, et al. Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2015;8:1059–1067.
- David V, Francis C, Babitt JL. Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol. 2017;312:1–8.
- Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant. 2012;27:2650.
- Goldsweig BK, Carpenter TO. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Curr Osteoporos Rep. 2015;13:88–97.
- Brandenburg VM, Ketteler M, Frank RD, et al. Bone pain with scintigraphy suggestive of widespread metastases –do not forget phosphate. Nephrol Dial Transplant. 2002;17:504–507.
- Prié D, Friedlander G. Reciprocal Control of 1,25-Dihydroxyvitamin D and FGF23 Formation Involving the FGF23/Klotho System. Clin J Am Soc Nephrol. 2010;5:1717–1722.
- Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild and Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–2608.
- Udell JA, Morrow DA, Jarolim P, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014;63:2421–2428.
- Smith ER, Cai MM, McMahon LP, et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97:3357–3363.
- Tholen DW, Kallner A, Kennedy JW, et al. Evaluation of precision performance of quantitative measurement methods;approved guideline. 2nd ed. Wayne (PA): NCCLS;2004.
- Horn PS, Pesce AJ. Reference intervals: user’s guide. Washington DC;AACC press;2005.
- Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8:332–337.
- Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I. J Clin Chem Clin Biochem. 1983;21:709–720.
- Souberbielle JC, Prié D, Piketty ML, et al. Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int. 2017;101:510–518.
- Devaraj S, Duncan-Staley BS, Jialal I. Evaluation of a method for fibroblast growth factor-, Tomaschitz A, 23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord. 2010;8:477–482.
- Shimizu Y, Fukumoto S, Fujita T. Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab. 2012;30:217–221.
- Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory levels of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin Endocrinol Metab. 2002;87:4957–4960.
- Smith ER, McMahon LP, Holt SG. Method-specific differences in plasma fibroblast growth factor 23 measurement using commercial ELISAs. Clin Chem Lab Med. 2013;51:1971–1981.
- Zuvela E, Walls M, Matson P. Within-laboratory and between-laboratory variability in the measurement of anti-Mullerian hormone determined within an external quality assurance scheme. Reproductive Biol. 2013;13:255–257.